| Literature DB >> 28126361 |
Emerith Mayra Hungria1, Aline Araújo Freitas1, Maria Araci Andrade Pontes2, Heitor Sá Gonçalves2, Ana Lúcia Osório Maroccolo Sousa1, Maurício Barcelos Costa1, Mirian Lane Oliveira Rodrigues Castilho3, Malcolm S Duthie4, Mariane Martins Araújo Stefani5.
Abstract
To advance toward a whole blood assay (WBA)-based test capable of facilitating the diagnosis of paucibacillary (PB) leprosy, we evaluated a prototype in-tube WBA using combinations of Mycobacterium leprae antigens. Blood was collected from newly diagnosed untreated PB (n=38), multibacillary (MB) (n=30), healthy household contacts (HHC) of MB (n=27), and endemic controls (n=61) residing in Goiânia and Fortaleza, Brazil. Blood was incubated with M. leprae cell sonicate, recombinant proteins (46f+LID-1; ML0276+LID-1), or controls (phosphate-buffered saline, phytohemagglutinin, M. tuberculosis purified protein derivative). Antigen-specific IFNγ production was observed in 71-84% and 55% of PB and HHC, respectively. Antigen-specific CXCL10 levels were similarly assessed to determine if, unlike IFNγ, CXCL10 could differentiate PB from HHC with repeated exposure/asymptomatic M. leprae infection. The CXCL10 levels induced in response to M. leprae antigens could not, however, differentiate PB from HHC. Despite these limitations, the WBAs reported here still represent important tools for assessing M. leprae infection rates and evaluating the impact of control measures.Entities:
Keywords: CXCL10; Cell-mediated immunity; Diagnosis; IFNγ; Leprosy; Whole blood assay
Mesh:
Substances:
Year: 2017 PMID: 28126361 DOI: 10.1016/j.diagmicrobio.2017.01.002
Source DB: PubMed Journal: Diagn Microbiol Infect Dis ISSN: 0732-8893 Impact factor: 2.803